vs
Adaptive Biotechnologies Corp（ADPT）与Aligos Therapeutics, Inc.（ALGS）财务数据对比。点击上方公司名可切换其他公司
Adaptive Biotechnologies Corp的季度营收约是Aligos Therapeutics, Inc.的424.1倍（$71.7M vs $169.0K）。Adaptive Biotechnologies Corp净利率更高（-18.9% vs -11763.9%，领先11745.0%）。Adaptive Biotechnologies Corp同比增速更快（51.0% vs -72.1%）。过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs -50.7%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
ADPT vs ALGS — 直观对比
营收规模更大
ADPT
是对方的424.1倍
$169.0K
营收增速更快
ADPT
高出123.1%
-72.1%
净利率更高
ADPT
高出11745.0%
-11763.9%
两年增速更快
ADPT
近两年复合增速
-50.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $169.0K |
| 净利润 | $-13.6M | $-19.9M |
| 毛利率 | 74.6% | — |
| 营业利润率 | -17.8% | -12907.7% |
| 净利率 | -18.9% | -11763.9% |
| 营收同比 | 51.0% | -72.1% |
| 净利润同比 | 59.7% | 75.8% |
| 每股收益（稀释后） | $-0.08 | $4.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTALGS
| Q4 25 | $71.7M | $169.0K | ||
| Q3 25 | $94.0M | $741.0K | ||
| Q2 25 | $58.9M | $965.0K | ||
| Q1 25 | $52.4M | $311.0K | ||
| Q4 24 | $47.5M | $606.0K | ||
| Q3 24 | $46.4M | $1.3M | ||
| Q2 24 | $43.2M | $1.1M | ||
| Q1 24 | $41.9M | $694.0K |
净利润ADPTALGS
| Q4 25 | $-13.6M | $-19.9M | ||
| Q3 25 | $9.5M | $-31.5M | ||
| Q2 25 | $-25.6M | $-15.9M | ||
| Q1 25 | $-29.9M | $43.1M | ||
| Q4 24 | $-33.7M | $-82.2M | ||
| Q3 24 | $-32.1M | $-19.3M | ||
| Q2 24 | $-46.2M | $5.1M | ||
| Q1 24 | $-47.5M | $-34.9M |
毛利率ADPTALGS
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
营业利润率ADPTALGS
| Q4 25 | -17.8% | -12907.7% | ||
| Q3 25 | 10.9% | -3827.4% | ||
| Q2 25 | -42.5% | -1924.0% | ||
| Q1 25 | -56.4% | -6187.5% | ||
| Q4 24 | -71.3% | -3393.2% | ||
| Q3 24 | -70.3% | -1610.5% | ||
| Q2 24 | -109.6% | -2489.5% | ||
| Q1 24 | -116.5% | -3176.7% |
净利率ADPTALGS
| Q4 25 | -18.9% | -11763.9% | ||
| Q3 25 | 10.2% | -4256.0% | ||
| Q2 25 | -43.5% | -1643.8% | ||
| Q1 25 | -56.9% | 13854.7% | ||
| Q4 24 | -71.0% | -13556.1% | ||
| Q3 24 | -69.1% | -1540.7% | ||
| Q2 24 | -107.0% | 477.0% | ||
| Q1 24 | -113.5% | -5023.5% |
每股收益（稀释后）ADPTALGS
| Q4 25 | $-0.08 | $4.23 | ||
| Q3 25 | $0.06 | $-3.04 | ||
| Q2 25 | $-0.17 | $-1.53 | ||
| Q1 25 | $-0.20 | $-2.11 | ||
| Q4 24 | $-0.22 | $-13.10 | ||
| Q3 24 | $-0.22 | $-3.07 | ||
| Q2 24 | $-0.31 | $0.81 | ||
| Q1 24 | $-0.33 | $-5.58 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $77.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $218.8M | $53.5M |
| 总资产 | $512.7M | $88.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADPTALGS
| Q4 25 | $70.5M | $77.8M | ||
| Q3 25 | $55.0M | $99.1M | ||
| Q2 25 | $43.2M | $122.9M | ||
| Q1 25 | $50.6M | $137.9M | ||
| Q4 24 | $47.9M | $56.9M | ||
| Q3 24 | $38.1M | $74.9M | ||
| Q2 24 | $59.8M | $94.5M | ||
| Q1 24 | $71.2M | $112.7M |
股东权益ADPTALGS
| Q4 25 | $218.8M | $53.5M | ||
| Q3 25 | $204.4M | $71.8M | ||
| Q2 25 | $179.7M | $101.9M | ||
| Q1 25 | $190.4M | $116.4M | ||
| Q4 24 | $202.7M | $-29.0M | ||
| Q3 24 | $223.8M | $50.1M | ||
| Q2 24 | $241.6M | $67.2M | ||
| Q1 24 | $274.9M | $59.8M |
总资产ADPTALGS
| Q4 25 | $512.7M | $88.5M | ||
| Q3 25 | $490.6M | $109.8M | ||
| Q2 25 | $496.6M | $134.7M | ||
| Q1 25 | $510.9M | $150.7M | ||
| Q4 24 | $539.4M | $70.1M | ||
| Q3 24 | $558.5M | $88.4M | ||
| Q2 24 | $584.9M | $108.8M | ||
| Q1 24 | $620.3M | $127.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $-21.7M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | — |
| 自由现金流率自由现金流/营收 | 2.0% | — |
| 资本支出强度资本支出/营收 | 0.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-48.9M | — |
8季度趋势，按日历期对齐
经营现金流ADPTALGS
| Q4 25 | $2.1M | $-21.7M | ||
| Q3 25 | $-7.1M | $-24.3M | ||
| Q2 25 | $-12.4M | $-15.5M | ||
| Q1 25 | $-28.5M | $-20.9M | ||
| Q4 24 | $-12.5M | $-18.4M | ||
| Q3 24 | $-27.1M | $-20.1M | ||
| Q2 24 | $-17.3M | $-19.5M | ||
| Q1 24 | $-38.4M | $-22.7M |
自由现金流ADPTALGS
| Q4 25 | $1.4M | — | ||
| Q3 25 | $-7.5M | — | ||
| Q2 25 | $-13.1M | — | ||
| Q1 25 | $-29.7M | — | ||
| Q4 24 | $-12.6M | — | ||
| Q3 24 | $-27.4M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-39.9M | — |
自由现金流率ADPTALGS
| Q4 25 | 2.0% | — | ||
| Q3 25 | -8.0% | — | ||
| Q2 25 | -22.2% | — | ||
| Q1 25 | -56.7% | — | ||
| Q4 24 | -26.5% | — | ||
| Q3 24 | -59.0% | — | ||
| Q2 24 | -44.1% | — | ||
| Q1 24 | -95.2% | — |
资本支出强度ADPTALGS
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 3.6% | — |
现金转化率ADPTALGS
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.85× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
ALGS
暂无分部数据
